Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1813337
PUBLISHER: BCC Research | PRODUCT CODE: 1813337
mRNA: Therapeutics and Global Markets
PUBLISHED:
PAGES: 131 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a compound annual growth rate (CAGR) of -0.04% during the forecast period of 2025 to 2030.
The global market for COVID mRNA therapeutics was valued at $7.65 billion in 2025 and is forecast to slightly decline to $7.58 billion by the end of 2030, at a CAGR of -0.2% during the forecast period of 2025 to 2030.
The global market for non-COVID diseases mRNA therapeutics was valued at $61.7 million in 2025 and is forecast to reach $118.9 million by the end of 2030, at a CAGR of 14% during the forecast period of 2025 to 2030.
Report Scope
The report analyzes the global market for mRNA therapeutics. It includes global revenue ($ millions) for the base year of 2024, estimated data for 2025 and projected compound annual growth rates (CAGRs) through 2030. The report examines the different types of mRNA and their applications for therapeutic use. It also focuses on mRNA patents and clinical trials and examines the trends affecting the market during the forecast period. The report profiles the leading companies and their strategic alliances and partnerships. The report segments the global market into North America, Europe, Asia-Pacific (APAC) and the Rest of the World (RoW).
Report Includes
- 19 data tables and 71 additional tables
- An overview and analysis of the global markets for messenger RNA (mRNA)-based therapeutics
- Analyses of the global market trends, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
- Estimates of the size and revenue prospects for the global mRNA market, along with a market share analysis by disease type, indication, and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
- Insights derived from Porter's Five Forces model, global supply chain and PESTLE analyses
- Patent analysis, featuring key granted and published patents
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Moderna Inc., Pfizer Inc., BioNTech SE, Merck & Co., and Sanofi
Product Code: BIO212C
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Growth Factors
- Emerging Technologies
- COVID mRNA Vaccines
- Regional Analysis
- Conclusion
Chapter 2 Market Overview
- Technology Background
- Evolution of RNA Therapeutics
- DNA Therapeutics vs. RNA Therapeutics
- RNA Therapeutics
- mRNA as Therapeutics
- Regulatory Agency-Approved mRNA Vaccines
- Porter's Five Forces Analysis
- Potential for New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitute Products or Services
- Industry Competition
- Impact of U.S. Tariffs on the mRNA Therapeutics Market
- Conclusion
Chapter 3 Market Dynamics
- Overview
- Market Drivers
- Rising Numbers of Pandemics and Epidemics
- Awareness of the Need for Vaccinations
- Investments in mRNA Therapeutics Research
- Market Restraints
- Limitations of mRNA Vaccines
- Production and Logistical Hurdles
- Market Opportunities
- Personalized Cancer Vaccines
- Potential of mRNA Drugs to Treat Various Diseases
Chapter 4 Regulatory Landscape
- Regulatory Scenario
- Overview of Regulatory Bodies
- Guidelines and Standards for mRNA Vaccines
- Preclinical and Clinical Evaluation
- Manufacturing and Post-Marketing Surveillance
- Continual Monitoring and Risk Management
Chapter 5 Pipeline and Clinical Trial Analysis
- Takeaways
- mRNA Vaccines
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Market Breakdown by Disease Type
- Takeaways
- COVID mRNA Vaccines
- Non-COVID mRNA Vaccines and Therapeutics
- Market Breakdown by Indication
- Cancer
- Infectious Diseases
- Rare Diseases
- Others
- Geographic Breakdown
- Market Breakdown, by Region
- Takeaways
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Emerging Technologies and Developments
- Emerging Technologies in mRNA Therapeutics
- Nanoparticles
- Modified mRNA
- Automated mRNA Synthesis Kits
- Bio Platforms
- Artificial Intelligence
- AI Developments at mRNA Therapeutics Companies
Chapter 8 Patent Analysis
- Takeaways
- mRNA Publications
- List of Patents
Chapter 9 Sustainability in the mRNA Therapeutics Industry: An ESG Perspective
- Sustainability in the mRNA Therapeutics Industry
- ESG Risk Ratings
- ESG Performance Analysis
- Environmental Performance
- Social Performance
- Governance Performance
- Concluding Remarks from BCC Research
Chapter 10 Competitive Intelligence
- Takeaways
- Leading Companies in the mRNA Therapeutics Market, 2024
- Strategic Analysis
- Collaborations and Partnerships
- Regulatory Approvals
- Clinical Trials Data
- Funding and Grants
Chapter 11 Appendix
- Methodology
- Abbreviations
- Sources
- Company Profiles
- ARCTURUS THERAPEUTICS INC.
- ASTRAZENECA
- BIOCINA
- BIONTECH SE
- CUREVAC SE
- ETHRIS GMBH
- GENNOVA BIOPHARMACEUTICALS LTD.
- GSK PLC.
- IMMORNA (HANGZHOU) BIOTECHNOLOGY CO. LTD.
- MERCK & CO. INC.
- MODERNA INC.
- NUTCRACKER THERAPEUTICS INC.
- PFIZER INC.
- PROVIDENCE THERAPEUTICS
- SANOFI
- STRAND THERAPEUTICS INC.
Product Code: BIO212C
List of Tables
- Summary Table : Global Market for mRNA Therapeutics, by Disease, Through 2030
- Table 1 : Evolution of RNA Therapeutics
- Table 2 : Approved mRNA Vaccines, 2025
- Table 3 : Pandemics of the 21st Century
- Table 4 : Status of Clinical Trials for mRNA-based Drugs, 2025
- Table 5 : Clinical Trials for mRNA Vaccines, 2025
- Table 6 : Global Market for mRNA Therapeutics, by Disease Type, Through 2030
- Table 7 : Properties of the BNT162b2 Vaccine
- Table 8 : Properties of the mRNA-1273 Vaccine
- Table 9 : Properties of the CVnCoV Vaccine
- Table 10 : Global Market for COVID mRNA Therapeutics, by Region, Through 2030
- Table 11 : Global Market for Non-COVID mRNA Vaccines and Therapeutics, by Region, Through 2030
- Table 12 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
- Table 13 : Global Market for mRNA Therapeutics, by Region, Through 2030
- Table 14 : North American Market for mRNA Therapeutics, by Disease Type, Through 2030
- Table 15 : European Market for mRNA Therapeutics, by Disease Type, Through 2030
- Table 16 : Asia-Pacific Market for mRNA Therapeutics, by Disease Type, Through 2030
- Table 17 : RoW Market for mRNA Therapeutics, by Disease Type, Through 2030
- Table 18 : Organizations with the Most Published mRNA Patents
- Table 19 : Patents for mRNA Therapeutics, 2025
- Table 20 : Patents Related to mRNA Vaccines for Infectious Diseases, 2025
- Table 21 : Patents Related to mRNA Vaccines for Cancer Treatment, 2025
- Table 22 : Patents Focused on mRNA Delivery and Modification
- Table 23 : Focus Areas in ESG Metrics
- Table 24 : ESG Rankings for Major mRNA Therapeutics Companies, 2025*
- Table 25 : ESG: Environmental Overview
- Table 26 : ESG: Social Factors Overview
- Table 27 : ESG: Governance Overview
- Table 28 : Collaborations and Partnerships in the mRNA Therapeutics Market, 2023-2025
- Table 29 : Regulatory Approvals in the mRNA Therapeutics Industry, 2023-2025
- Table 30 : Clinical Trial Data in the mRNA Therapeutics Market, 2022-2025
- Table 31 : Funding and Grants in the mRNA Therapeutics Market, 2023-2025
- Table 32 : Abbreviations Used in this Report
- Table 33 : Arcturus Therapeutics Inc.: Company Snapshot
- Table 34 : Arcturus Therapeutics Inc.: Financial Performance, FY 2023 and 2024
- Table 35 : Arcturus Therapeutics Inc.: Product Pipeline
- Table 36 : Arcturus Therapeutics Inc.: News/Key Developments, 2024-2025
- Table 37 : AstraZeneca: Company Snapshot
- Table 38 : AstraZeneca: Financial Performance, FY 2023 and 2024
- Table 39 : AstraZeneca: Product Pipeline
- Table 40 : AstraZeneca: News/Key Developments, 2025
- Table 41 : BioCina: Company Snapshot
- Table 42 : BioCina: Product Portfolio
- Table 43 : BioCina: News/Key Developments, 2023-2025
- Table 44 : BioNTech SE: Company Snapshot
- Table 45 : BioNTech SE: Financial Performance, FY 2023 and 2024
- Table 46 : BioNTech SE: Product Pipeline
- Table 47 : BioNTech SE: News/Key Developments, 2023-2024
- Table 48 : CureVac SE: Company Snapshot
- Table 49 : CureVac SE: Financial Performance, FY 2023 and 2024
- Table 50 : CureVac SE: Product Pipeline
- Table 51 : CureVac SE: News/Key Developments, 2024-2025
- Table 52 : Ethris GmbH: Company Snapshot
- Table 53 : Ethris GmbH: Product Pipeline
- Table 54 : Ethris GmbH: News/Key Developments, 2023-2025
- Table 55 : Gennova Biopharmaceuticals Ltd.: Company Snapshot
- Table 56 : Gennova Biopharmaceuticals Ltd.: Product Portfolio
- Table 57 : Gennova Biopharmaceuticals Ltd.: News/Key Developments, 2023
- Table 58 : GSK PLC: Company Snapshot
- Table 59 : GSK PLC: Financial Performance, FY 2023 and 2024
- Table 60 : GSK PLC: Product Pipeline
- Table 61 : GSK PLC: News/Key Developments, 2024
- Table 62 : Immorna Biotechnology Co. Ltd.: Company Snapshot
- Table 63 : Immorna Biotechnology Co. Ltd.: Product Pipeline
- Table 64 : Immorna Biotechnology Co. Ltd: News/Key Developments, 2024-2025
- Table 65 : Merck & Co. Inc.: Company Snapshot
- Table 66 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
- Table 67 : Merck & Co. Inc.: Product Pipeline
- Table 68 : Merck & Co. Inc.: News/Key Developments, 2023
- Table 69 : Moderna Inc.: Company Snapshot
- Table 70 : Moderna Inc.: Financial Performance, FY 2023 and 2024
- Table 71 : Moderna Inc.: Product Pipeline
- Table 72 : Moderna Inc.: News/Key Developments, 2024-2025
- Table 73 : Nutcracker Therapeutics Inc.: Company Snapshot
- Table 74 : Nutcracker Therapeutics Inc.: Product Portfolio
- Table 75 : Nutcracker Therapeutics Inc.: News/Key Developments, 2024-2025
- Table 76 : Pfizer Inc.: Company Snapshot
- Table 77 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
- Table 78 : Pfizer Inc.: Product Portfolio
- Table 79 : Pfizer Inc.: News/Key Developments, 2024
- Table 80 : Providence Therapeutics: Company Snapshot
- Table 81 : Providence Therapeutics: Product Pipeline
- Table 82 : Providence Therapeutics: News/Key Developments, 2022-2024
- Table 83 : Sanofi: Company Snapshot
- Table 84 : Sanofi: Financial Performance, FY 2023 and 2024
- Table 85 : Sanofi: Product Pipeline
- Table 86 : Sanofi: News/Key Developments, 2024-2025
- Table 87 : Strand Therapeutics Inc.: Company Snapshot
- Table 88 : Strand Therapeutics Inc.: Product Pipeline
- Table 89 : Strand Therapeutics Inc.: News/Key Developments, 2024-2025
List of Figures
- Summary Figure : Global Market Shares of mRNA Therapeutics, by Disease, 2024
- Figure 1 : Porter's Five Forces Analysis
- Figure 2 : Snapshot of Market Dynamics
- Figure 3 : Factors Responsible for the Rising Number of Pandemics
- Figure 4 : Clinical Trials for mRNA Vaccines, by Disease Indication, 2023-2025
- Figure 5 : mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023-2025
- Figure 6 : mRNA Vaccine Candidates in Clinical Trials, by Study Type, 2023-2025
- Figure 7 : mRNA Vaccine Candidates in Clinical Trials, by Funding Source, 2023-2025
- Figure 8 : Global Market Shares of mRNA Therapeutics, by Disease Type, 2024
- Figure 9 : Global Cancer-Related Deaths, by Cancer Type, 2000-2030
- Figure 10 : Global Market Shares of mRNA Therapeutics, by Region, 2024
- Figure 11 : Emerging Technologies in mRNA Therapeutics
- Figure 12 : Patents on mRNA Therapeutics, 2010-2022
- Figure 13 : Patent Shares on mRNA Therapeutics, by Patent Classification, 2010-2021
- Figure 14 : Published mRNA-based Patents, 2019-2022
- Figure 15 : How a Strong ESG Proposition Can Benefit Businesses
- Figure 16 : Moderna's mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
- Figure 17 : BioNTech's mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
- Figure 18 : Arcturus Therapeutics Inc: Revenue Shares, by Business Unit, FY 2024
- Figure 19 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
- Figure 20 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
- Figure 21 : BioNTech SE: Revenue Shares, by Region/Country, FY 2024
- Figure 22 : GSK PLC: Revenue Shares, by Business Unit, FY 2024
- Figure 23 : GSK PLC: Revenue Shares, by Region/Country, FY 2024
- Figure 24 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 25 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 26 : Moderna Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 27 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 28 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 29 : Sanofi: Revenue Shares, by Country/Region, FY 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.